跳至主要内容
临床试验/NCT07624994
NCT07624994尚未招募2 期

Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study

Centre Jean Perrin2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2026年8月1日最近更新:
干预措施

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
80
试验地点
2

研究概览

简要总结

This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Karnofsky index > 70%
  • Obtaining written, signed and dated informed consent
  • Affiliation to a health insurance plan
  • For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.
  • Ability and willingness to respect study visits, exams as well as protocol.
  • certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria,
  • symptomatic (finger pain > 4 /10 on a numerical scale),
  • active synovitis (clinical and ultrasound),
  • certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale),
  • stopping NSAIDs for at least 8 days before the injection,

排除标准

  • Ongoing use of non-steroidal anti-inflammatory drugs,
  • Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,
  • History of osteoarticular hand surgery.
  • History of hand soft tissue surgery in the past 6 months
  • Patients or patients 18 years old,
  • Pregnant or breastfeeding patient,
  • History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,
  • Persons deprived of their liberty, under guardianship/curatorship, or safeguarding of justice,
  • Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.
  • Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.
  • Patients with a history of hand DOA

研究组 & 干预措施

digital osteoarthritis

Experimental

99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg

干预措施: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (Drug)

Rheumatoid arthritis

Experimental

99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg

干预措施: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (Drug)

研究者

发起方
Centre Jean Perrin
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验